The global central nervous system therapeutic market accounted for USD 112.91 billion in 2023 and is expected to reach USD 215.19 billion by 2034 with a CAGR of 6.07% during the forecast period 2024-2034. The market will grow as a result of factors such as the rising prevalence of CNS disorders, increased attention being paid to mental health, innovative CNS therapies, an aging population, increased government funding and initiatives, and strategic alliances and collaborations.
Important factors include the increased incidence and prevalence of CNS conditions such as multiple sclerosis, depression, anxiety disorders, Parkinson's disease, Alzheimer's disease, and epilepsy. It is anticipated that the burden of these diseases will rise with aging populations and changing lifestyles, increasing the need for efficient therapies. For instance, in December 2023, Novartis AG received FDA approval for a new medication for migraines. This broadens their offering in the field of CNS pain management.
By disease, the neurodegenerative disease segment accounted for the highest revenue segment in the global central nervous system therapeutic market in 2023 owing to the increasing prevalence of conditions like Alzheimer's and Parkinson's, advancements in research leading to new treatment options, and the rising aging population worldwide. Additionally, greater awareness and early diagnosis contribute to the demand for neurodegenerative disease treatments. For instance, in January 2024, Johnson & Johnson and Biogen partnered to co-develop and market a novel medication for ALS (amyotrophic lateral sclerosis). They are working together to expedite development by pooling their resources and expertise. Additionally, the CNS cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of CNS tumors, advancements in diagnostic techniques allowing for early detection, development of targeted therapies, and growing investment in oncology research and development.
By drug class, the antidepressants segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutic market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of depression and mood disorders globally, increased acceptance of mental health treatment, expanding awareness campaigns, and the introduction of novel antidepressant drugs with improved efficacy and fewer side effects. For instance, in December 2023, the Bristol Myers Squibb Company expanded its current partnership with RXi Pharmaceuticals to explore next-generation medicines for CNS illnesses, including schizophrenia.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutic market in 2023 owing to the growing accessibility and convenience of retail pharmacies, rising demand for over-the-counter and prescription CNS medications, expansion of retail pharmacy chains, and increasing self-medication trends. For instance, in February 2024 Teva Pharmaceutical Industries Ltd. introduced a generic version of a popular ADHD drug to the US market. This broadens their selection of generic CNS medications and makes more reasonably priced treatments available to patients. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized neurological and psychiatric care, increasing prevalence of complex CNS disorders requiring multidisciplinary approaches, advancements in treatment modalities offered by specialty clinics, and growing investments in healthcare infrastructure and technology.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established healthcare infrastructure, high adoption rates of advanced CNS therapeutics, robust research and development activities, increasing prevalence of CNS disorders, favorable reimbursement policies, and growing awareness about mental health issues. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing healthcare expenditure, expanding access to healthcare services, rising prevalence of CNS disorders due to demographic shifts and lifestyle changes, growing investments in healthcare infrastructure, and rising awareness about mental health issues in the region. For instance, in December 2023, Otsuka Pharmaceutical Co., Ltd. was granted permission to market a novel antiepileptic medication within the European Union. This increases their market penetration for epilepsy treatments.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Important factors include the increased incidence and prevalence of CNS conditions such as multiple sclerosis, depression, anxiety disorders, Parkinson's disease, Alzheimer's disease, and epilepsy. It is anticipated that the burden of these diseases will rise with aging populations and changing lifestyles, increasing the need for efficient therapies. For instance, in December 2023, Novartis AG received FDA approval for a new medication for migraines. This broadens their offering in the field of CNS pain management.
By disease, the neurodegenerative disease segment accounted for the highest revenue segment in the global central nervous system therapeutic market in 2023 owing to the increasing prevalence of conditions like Alzheimer's and Parkinson's, advancements in research leading to new treatment options, and the rising aging population worldwide. Additionally, greater awareness and early diagnosis contribute to the demand for neurodegenerative disease treatments. For instance, in January 2024, Johnson & Johnson and Biogen partnered to co-develop and market a novel medication for ALS (amyotrophic lateral sclerosis). They are working together to expedite development by pooling their resources and expertise. Additionally, the CNS cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of CNS tumors, advancements in diagnostic techniques allowing for early detection, development of targeted therapies, and growing investment in oncology research and development.
By drug class, the antidepressants segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutic market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of depression and mood disorders globally, increased acceptance of mental health treatment, expanding awareness campaigns, and the introduction of novel antidepressant drugs with improved efficacy and fewer side effects. For instance, in December 2023, the Bristol Myers Squibb Company expanded its current partnership with RXi Pharmaceuticals to explore next-generation medicines for CNS illnesses, including schizophrenia.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutic market in 2023 owing to the growing accessibility and convenience of retail pharmacies, rising demand for over-the-counter and prescription CNS medications, expansion of retail pharmacy chains, and increasing self-medication trends. For instance, in February 2024 Teva Pharmaceutical Industries Ltd. introduced a generic version of a popular ADHD drug to the US market. This broadens their selection of generic CNS medications and makes more reasonably priced treatments available to patients. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized neurological and psychiatric care, increasing prevalence of complex CNS disorders requiring multidisciplinary approaches, advancements in treatment modalities offered by specialty clinics, and growing investments in healthcare infrastructure and technology.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established healthcare infrastructure, high adoption rates of advanced CNS therapeutics, robust research and development activities, increasing prevalence of CNS disorders, favorable reimbursement policies, and growing awareness about mental health issues. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing healthcare expenditure, expanding access to healthcare services, rising prevalence of CNS disorders due to demographic shifts and lifestyle changes, growing investments in healthcare infrastructure, and rising awareness about mental health issues in the region. For instance, in December 2023, Otsuka Pharmaceutical Co., Ltd. was granted permission to market a novel antiepileptic medication within the European Union. This increases their market penetration for epilepsy treatments.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Disease, Drug Class, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Central Nervous System Therapeutic Market Report 2023 - 2034
Central Nervous System Therapeutic Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Neurovascular Diseases
- CNS Trauma
- Mental Health
- Anxiety Disorders
- Epilepsy
- Mood Disorders
- Psychotic Disorders
- Others
- Neurodegenerative Diseases
- Alzheimer's Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Huntington's Disease
- Amyotrophic Lateral Sclerosis
- Others
- Infectious Diseases
- CNS Cancer
- Others
Central Nervous System Therapeutic Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Analgesics
- Antidepressants
- Anesthetics
- Anti-Parkinson Drugs
- Anti-Epileptics
- Other Drug Classes
Central Nervous System Therapeutic Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Hospitals
- Specialty clinics
Central Nervous System Therapeutic Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Central Nervous System Therapeutic Market: Disease Estimates & Trend Analysis
8. Central Nervous System Therapeutic Market: Drug Class Estimates & Trend Analysis
9. Central Nervous System Therapeutic Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Central Nervous System Therapeutic Market
12. Europe Global Central Nervous System Therapeutic Market
13. Asia Pacific Global Central Nervous System Therapeutic Market
14. Latin America Global Central Nervous System Therapeutic Market
15. MEA Global Central Nervous System Therapeutic Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson
- Novartis AG
- Eli Lilly and Company
- Merck & Co. Inc.
- AbbVie Inc.
- AstraZeneca PLC
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- UCB S.A.
- Eisai Co. Ltd.
- Lundbeck A/S
